Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Activation of the alternative complement pathway by Haemophilus influenzae type B.

Literature DB >> 301507

Activation of the alternative complement pathway by Haemophilus influenzae type B.

P H Quinn, F J Crosson, J A Winkelstein, E R Moxon.

Abstract

The results of the following study demonstrate that Haemophilus influenzae type B (HITB) is able to activate the alternative complement pathway. They also demonstrate that the activation of the alternative pathway by HITB is not mediated by the capsule.

Entities: Species

Mesh：

Substances：

Year: 1977 PMID： 301507 PMCID： PMC421534 DOI： 10.1128/iai.16.1.400-402.1977

Source DB: PubMed Journal: Infect Immun ISSN： 0019-9567 Impact factor: 3.441

9 in total

1. Participation of complement in the nonimmune host defense against experimental Haemophilus influenzae type b septicemia and meningitis.

Authors: F J Crosson; J A Winkelstein; E R Moxon
Journal: Infect Immun Date: 1976-10 Impact factor: 3.441

2. Haemophilus influenzae meningitis in infant rats after intranasal inoculation.

Authors: E R Moxon; A L Smith; D R Averill; D H Smith
Journal: J Infect Dis Date: 1974-02 Impact factor: 5.226

3. Heat labile opsonins to Pneumococcus. 3. The participation of immunoglobulin and of the alternate pathway of C3 activation.

Authors: J A Winkelstein; H S Shin; W B Wood
Journal: J Immunol Date: 1972-06 Impact factor: 5.422

Review 4. The complement system of man. I.

Authors: S Ruddy; I Gigli; K F Austen
Journal: N Engl J Med Date: 1972-09-07 Impact factor: 91.245

5. The third component of the guinea pig complement system. II. Kinetic study of the reaction of EAC'4,2a with guinea pig C'3. Enzymatic nature of C'3 comsumption, multiphasic character of fixation, and hemolytic titration of C'3.

Authors: H S Shin; M M Mayer
Journal: Biochemistry Date: 1968-08 Impact factor: 3.162

6. Activation of the alternative (properdin) pathway by divalent cations.

Authors: F T Lew; Y Yukiyama; H S Waks; A G Osler
Journal: J Immunol Date: 1975-09 Impact factor: 5.422

7. Human serum activities against Hemophilus influenzae, type b.

Authors: P Anderson; R B Johnston; D H Smith
Journal: J Clin Invest Date: 1972-01 Impact factor: 14.808

8. Genetically controlled total deficiency of the fourth component of complement in the guinea pig.

Authors: L Ellman; I Green; M Frank
Journal: Science Date: 1970-10-02 Impact factor: 47.728

9. Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Authors: E C Gotschlich; T Y Liu; M S Artenstein
Journal: J Exp Med Date: 1969-06-01 Impact factor: 14.307

9 in total

16 in total

Review 1. Clinical implications of the specialised B cell response to polysaccharide encapsulated pathogens.

Authors: C G Vinuesa; C de Lucas; M C Cook
Journal: Postgrad Med J Date: 2001-09 Impact factor: 2.401

2. Alternate complement pathway activation by group A streptococci: role of M-protein.

Authors: A L Bisno
Journal: Infect Immun Date: 1979-12 Impact factor: 3.441

3. Effect of amplification of the Cap b locus on complement-mediated bacteriolysis and opsonization of type b Haemophilus influenzae.

Authors: G J Noel; A Brittingham; A A Granato; D M Mosser
Journal: Infect Immun Date: 1996-11 Impact factor: 3.441

Activation of the alternative complement pathway by Haemophilus influenzae type B.

1. Participation of complement in the nonimmune host defense against experimental Haemophilus influenzae type b septicemia and meningitis.

2. Haemophilus influenzae meningitis in infant rats after intranasal inoculation.

3. Heat labile opsonins to Pneumococcus. 3. The participation of immunoglobulin and of the alternate pathway of C3 activation.

Review 4. The complement system of man. I.

5. The third component of the guinea pig complement system. II. Kinetic study of the reaction of EAC'4,2a with guinea pig C'3. Enzymatic nature of C'3 comsumption, multiphasic character of fixation, and hemolytic titration of C'3.

6. Activation of the alternative (properdin) pathway by divalent cations.

7. Human serum activities against Hemophilus influenzae, type b.

8. Genetically controlled total deficiency of the fourth component of complement in the guinea pig.

9. Human immunity to the meningococcus. 3. Preparation and immunochemical properties of the group A, group B, and group C meningococcal polysaccharides.

Review 1. Clinical implications of the specialised B cell response to polysaccharide encapsulated pathogens.

2. Alternate complement pathway activation by group A streptococci: role of M-protein.

3. Effect of amplification of the Cap b locus on complement-mediated bacteriolysis and opsonization of type b Haemophilus influenzae.

4. Mesophilic Aeromonas sp. serogroup O:11 resistance to complement-mediated killing.

5. Interaction of pneumococcal antigens with complement in rats.

Review 6. Pathogenesis and pathophysiology of bacterial meningitis.

7. Participation of complement in host defense against encapsulated Haemophilus influenzae types a, c, and d.

8. Role of complement in mouse macrophage binding of Haemophilus influenzae type b.

9. Differential complement resistance mediates virulence of Haemophilus influenzae type b.

10. Antibody-dependent alternative pathway killing of Haemophilus influenzae type b.